RO4491533

RO4491533
Clinical data
ATC code	None;
Legal status
Legal status	In general: non-regulated;
Identifiers
	IUPAC name 4-[3-(2,6-dimethylpyridin-4-yl)phenyl]-7-methyl-8-trifluoromethyl-1,3-dihydrobenzo[b][1,4]diazepin-2-one;
CAS Number	579482-31-8 ;
PubChem CID	11158623;
IUPHAR/BPS	6226;
ChemSpider	9333726;
UNII	HF59BT62UG;
CompTox Dashboard (EPA)	DTXSID601030327 ;
Chemical and physical data
Formula	C24H20F3N3O
Molar mass	423.439 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n3c(C)cc(cc3C)-c(ccc4)cc4C(=Nc1cc2C)CC(=O)Nc1cc2C(F)(F)F;
	InChI InChI=1S/C24H20F3N3O/c1-13-7-21-22(11-19(13)24(25,26)27)30-23(31)12-20(29-21)17-6-4-5-16(10-17)18-8-14(2)28-15(3)9-18/h4-11H,12H2,1-3H3,(H,30,31); Key:LYTVXCQQTLUEQR-UHFFFAOYSA-N;

RO-4491533 is a drug developed by Hoffmann-La Roche which acts as a potent and selective negative allosteric modulator for group II of the metabotropic glutamate receptors (mGluR_2/3), being equipotent at mGluR₂ and mGluR₃ but without activity at other mGluR subtypes. In animal studies, RO-4491533 produced antidepressant effects and reversed the effects of the mGluR_2/3 agonist LY-379,268 with similar efficacy but slightly lower potency than the mGluR_2/3 antagonist LY-341,495.^[1] A number of related compounds are known, with similar effects in vitro and a fairly well characterized structure-activity relationship.^[2]